CN107206107A - 用于玻璃体可视化的组合物和方法 - Google Patents

用于玻璃体可视化的组合物和方法 Download PDF

Info

Publication number
CN107206107A
CN107206107A CN201580045678.4A CN201580045678A CN107206107A CN 107206107 A CN107206107 A CN 107206107A CN 201580045678 A CN201580045678 A CN 201580045678A CN 107206107 A CN107206107 A CN 107206107A
Authority
CN
China
Prior art keywords
seq
composition
vitreous
eye
detectable moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580045678.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·高希
T·P·德瑞亚
M·罗古斯卡
E·卡尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN107206107A publication Critical patent/CN107206107A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
CN201580045678.4A 2014-06-25 2015-06-24 用于玻璃体可视化的组合物和方法 Pending CN107206107A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462016731P 2014-06-25 2014-06-25
US62/016,731 2014-06-25
PCT/IB2015/054747 WO2015198245A1 (en) 2014-06-25 2015-06-24 Compositions and methods for visualization of the vitreous

Publications (1)

Publication Number Publication Date
CN107206107A true CN107206107A (zh) 2017-09-26

Family

ID=53539753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580045678.4A Pending CN107206107A (zh) 2014-06-25 2015-06-24 用于玻璃体可视化的组合物和方法

Country Status (8)

Country Link
US (1) US10537648B2 (https=)
EP (1) EP3160512B1 (https=)
JP (2) JP6296581B2 (https=)
CN (1) CN107206107A (https=)
AU (1) AU2015278744B2 (https=)
CA (1) CA2953682A1 (https=)
ES (1) ES2730398T3 (https=)
WO (1) WO2015198245A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242919A1 (en) * 2024-05-24 2025-11-27 Navigo Proteins Gmbh Novel binding proteins for hyaluronic acid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135432A2 (en) * 2011-03-29 2012-10-04 Kemin Industries, Inc. Dyes for membranes and biological structures
WO2013063155A3 (en) * 2011-10-24 2013-07-11 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US8580735B2 (en) * 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
WO2014011813A1 (en) * 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733744A1 (en) 2005-06-17 2006-12-20 Ludwig-Maximilians-Universität München Method, dye and medicament for staining the internal limiting membrane and/or the capsule of an eye
JP4936508B2 (ja) * 2006-01-23 2012-05-23 独立行政法人国立国際医療研究センター 蛍光ナノ粒子を含む眼の硝子体染色剤及び染色方法
US20110236310A1 (en) 2008-12-25 2011-09-29 Canon Kabushiki Kaisha Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
GB201400994D0 (en) * 2014-01-21 2014-03-05 Ucl Business Plc Drug delivery system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580735B2 (en) * 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
WO2012135432A2 (en) * 2011-03-29 2012-10-04 Kemin Industries, Inc. Dyes for membranes and biological structures
WO2013063155A3 (en) * 2011-10-24 2013-07-11 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2014011813A1 (en) * 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof

Also Published As

Publication number Publication date
US20170202981A1 (en) 2017-07-20
CA2953682A1 (en) 2015-12-30
US10537648B2 (en) 2020-01-21
WO2015198245A1 (en) 2015-12-30
JP2017524679A (ja) 2017-08-31
EP3160512A1 (en) 2017-05-03
ES2730398T3 (es) 2019-11-11
AU2015278744A1 (en) 2017-01-12
JP2018039847A (ja) 2018-03-15
JP6296581B2 (ja) 2018-03-20
EP3160512B1 (en) 2019-05-22
AU2015278744B2 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
CN115066232B (zh) 用于治疗眼病的组合物和方法
ES2324485T3 (es) Composicion colorante para colorear una membrana oftalmica.
RU2561585C2 (ru) Местный глазной пептидный состав
EA013931B1 (ru) Способ лечения глазных расстройств
JP2023542939A (ja) ヒドロゲル及び活性薬剤を含む徐放性生分解性小管内挿入物
Cai et al. Injectable self-assembling peptide hydrogel as a promising vitreous substitute
Quiroz-Mendoza et al. Clinical trial of topical insulin and sodium hyaluronate in the treatment of epithelial defects produced by intraoperative corneal epithelial debridement during pars plana vitrectomy in diabetics
CN101125149A (zh) 眼科手术专用有色灌注液
CN109640973A (zh) 近视的治疗
Prieto et al. Safety study of intravitreal and suprachoroidal Laponite clay in rabbit eyes
US11160881B2 (en) Dendrimer compositions for use in angiography
CN107206107A (zh) 用于玻璃体可视化的组合物和方法
US20230256095A1 (en) Dyes for use in a method of treatment of vitreous opacity-related diseases
WO2023220676A9 (en) Chemerin-containing formulation for treating dry eye disease
Sarfare et al. Biocompatibility of a synthetic biopolymer for the treatment of rhegmatogenous retinal detachment
Gogate et al. The Concept of Ophthalmic Inserts as Drug Delivery Systems: An Insight
Qazi et al. An Age Based Differential Response of Dry Eye Disease on Topical Lubrication
Sohan et al. In-Situ Ocular Gel Pharmaceutical Delivery System: A Recent Review.
Jiang et al. The clinical therapeutic effect of ranibizumab intravitreous injection combined with phacoemulsification on diabetic macular edema
CN120399087A (zh) 一种类病毒结构纳米衔接器及其应用
KAPOOR et al. Optimization and Characterization of Gellan Gum Based Ocular In Situ Combigel Formulation of Gatifloxacin and Ketorolac.
Chaw Fundamental study of nanoliposomes for ocular therapy
CN115869416A (zh) 用于眼部靶向递药的细胞膜、药物载体、组合物及其制备方法和用途
Gore et al. A Review On: Ophthalmic Drug Dosage Form
Asensio et al. The effect of a combination of 0.1% tetracaine HCl and 0.4% oxybuprocaine HCl on human central corneal thickness measurements

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170926

WD01 Invention patent application deemed withdrawn after publication